Accordingly, amyloid PET is useful in identifying AD pathology as the underlying cause or comorbidity in patients with complex presentations, such as PPA variants or CBS,37, 38 particularly in the condition of DMT targeting Aβ. Here, CBS is linked to primary progressive aphasia.